Xuejuan Li

Dr. Xuejuan Li

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
XLXuejuan Li
Xuejuan Li
FLFangyuan Lai
Fangyuan Lai
ZJZhaohui Jiang
Zhaohui Jiang
MLMeng Li
Meng Li
ZCZebin Chen
Zebin Chen
FWFeiqiu Wen
Feiqiu Wen

3 December 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
ZCZhongqiang Cao
Zhongqiang Cao
JCJunjie Cheng
Junjie Cheng
ZCZebin Chen
Zebin Chen
XLXi Lei
Xi Lei
LYLing Yang
Ling Yang
XLXuejuan Li
Xuejuan Li
Although triptorelin acetate (TA) is generally considered a safe medication, severe adverse drug reactions (ADRs) to triptorelin have occurred. In this stu

8 July 2026 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
FLFangyuan Lai
Fangyuan Lai
ZDZhizhuo Du
Zhizhuo Du
LGLi Gao
Li Gao
JLJun Lu
Jun Lu
PXPeifang Xiao
Peifang Xiao
MZMi Zhou
Mi Zhou

1 November 2024 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
FLFangyuan Lai
Fangyuan Lai
XHXiuqiong Huang
Xiuqiong Huang
JPJiao Peng
Jiao Peng
NHNannan He
Nannan He
ZCZhongqiang Cao
Zhongqiang Cao
XLXuejuan Li
Xuejuan Li
Objective: The first-line treatment for severe Pneumocystis carinii pneumonia (PCP) is trimethoprim-sulfamethoxazole (TMP/SMZ). Here, we report a case involving 6-month-old child with a PCP infection, highlighting the role of clinical pharmacists in providing individualized pharmaceutical care and guidance through the process of therapeutic drug monitoring (TDM). Methods: The clinical pharmacist monitored the concentration of TMP/SMZ in the serum, urine and sputum of a 6-month-old child with PCP infection. To improve the serum levels of TMP/SMZ, the dose of TMP/SMZ was increased, while infusions of other medications were reduced to decrease the rate of drug excretion. Additionally, the patient received other supportive medications to enhance clinical therapeutic efficacy. Results: Clinical pharmacists observed that, despite administration of a sufficient dose of TMP/SMZ, plasma concentration of TMP/SMZ remained below the therapeutic window, while urine concentrations were extremely high. This phenomenon was attributed to Augmented Renal Clearance (ARC), often seen in critically ill patients and associated with increased renal clearance. Throughout treatment, the concentrations of SMZ remained below the minimum effective concentration, while the concentrations of TMP fell within the effective target range. However, sufficient therapeutic effects were ultimately achieved and observed in the patient, likely due to improved drug distribution in lung tissue (sputum) and the patient’s recovering immune functions. Finally, thanks to individualized pharmaceutical care from clinical pharmacists and the combined efforts of clinicians, the patient was discharged after 58 days of hospitalization. Conclusion: Throughout treatment, the clinical pharmacist played a vital role in optimizing the treatment plan based on the serum, urine and sputum concentrations of TMP/SMZ and providing pharmaceutical care to ensure a safe, rational and effective medications in children. Individualized dose adjustments, particularly high-dose TMP/SMZ guided by TDM, can significantly enhance the management of PCP in pediatric patients and support clinical pharmacists in delivering individualized pharmaceutical care.

15 September 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ZCZhongqiang Cao
Zhongqiang Cao
JCJunjie Cheng
Junjie Cheng
ZCZebin Chen
Zebin Chen
XLXi Lei
Xi Lei
LYLing Yang
Ling Yang
XLXuejuan Li
Xuejuan Li
Background: Although triptorelin acetate (TA) is generally considered a safe medication, severe adverse drug reactions (ADRs) to triptorelin have occurred. In this study, we present the largest retrospective analysis of ADRs related to TA during the treatment of pediatric central precocious puberty. Methods: We describe a total of 38 suspected cases of TA-induced ADRs reported to the pharma-covigilance center of Shenzhen Children’s Hospital from September 2015 to December 2022. Causality assessment was carried out using the validated Kramer’s algorithm. The severity of ADRs was evaluated using the Modified Hartwig and Siegel Scale. Results: The most common ADRs attributed to TA were damage to the cutaneous tissues (29.3%) and reactions affecting the systemic and digestive systems (20.7%). The majority (61.1%) of ADRs occurred within 2 hours of administration. Among the 12 patients with severe ADRs, the three most frequent symptoms were anaphylactic reactions, hip synovitis, and arthralgia. Additional-ly, six patients experienced ADRs due to a change in the manufacturing process. Conclusion: The majority of ADRs observed in pediatric cases were type I anaphylactic reactions, which are rare but life-threatening. It is advisable to perform skin prick tests and intradermal tests when switching pharmaceutical manufacturers.

7 October 2026 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
ZWZheng Wu
Zheng Wu
LZLixiang Zhu
Lixiang Zhu
YLYi Liu
Yi Liu
FLFangyuan Lai
Fangyuan Lai
ZCZebin Chen
Zebin Chen
XLXuejuan Li
Xuejuan Li
Objective: This study aims to develop a predictive model for cytarabine syndrome (CS)-related fever in pediatric patients with acute lymphoblastic leukemia (ALL). By integrating clinical features and laboratory indicators, we seek to establish an evidence-based diagnostic tool to assist clinicians in decision-making and optimize the use of antimicrobial agents. Methods: Study Design: A retrospective case-control study was conducted involving 72 ALL children (32 in the CS group vs. 40 in the infection group) who developed fever (≥37.5 °C) following cytarabine treatment. Model Development: Multivariate logistic regression was used to identify independent predictors. A nomogram was constructed. The model's discriminative ability was evaluated using the receiver operating characteristic (ROC) curve, calibration was assessed via the Hosmer-Lemeshow test, and clinical utility was validated using decision curve analysis (DCA). Results: Key Predictors: Multivariate analysis revealed that BSA (OR = 0.01, 95% CI: 0.00–0.17) and hs-CRP (OR = 0.84, 95% CI: 0.72–0.97) were the most significant predictors of CS. Model Performance: The ROC analysis demonstrated an AUC of 0.785, with internal validation via 1000 bootstrap resamples yielding a 95% confidence interval of 0.675–0.882. The calibration curve demonstrated excellent agreement between predicted and observed outcomes (MAE = 0.039). Decision curve analysis indicated that the model provided superior net benefits across most threshold probabilities (0.2–0.8) compared to strategies of universal antibiotic use or no intervention. Conclusion: The developed predictive model demonstrates high discriminative performance and robust clinical applicability, functioning as an effective quantitative instrument for early identification of cytarabine syndrome (CS) and facilitating evidence-based antibiotic stewardship.